Literature DB >> 7958985

Antisense oligodeoxyribonucleotide inhibition of TGF-beta 1 gene expression and alterations in the growth and malignant properties of mouse fibrosarcoma cells.

M Spearman1, W R Taylor, A H Greenberg, J A Wright.   

Abstract

Transforming growth factor (TGF-beta) is a family of multifunctional signalling molecules that play a fundamental role in both normal and malignant cell behavior. Procedures that alter mouse TGF-beta 1 gene expression provide an important approach for analyzing the complex regulatory processes associated with this member of the growth factor family. Therefore, we have designed oligodeoxyribonucleotides (oligos) in an antisense orientation, which are complementary to regions of the TGF-beta 1 message, in an attempt to obtain an oligo sequence that specifically reduces TGF-beta 1 synthesis. We observed that oligos containing a mixture of phosphorothioate and phosphodiester linkages were less toxic and more specific when compared to those only containing phosphorothioate. A non-toxic sequence was identified that markedly reduced the levels of TGF-beta 1 in oligo-treated malignant mouse fibrosarcoma cells. The invasive and metastatic properties of these fibrosarcoma cells were also significantly decreased following treatment with the antisense oligo. The results indicate an important role for altered TGF-beta 1 expression in the regulation of malignant cell proliferation, invasion and metastasis. These results also indicate that this oligo sequence is a useful tool for studies directed towards understanding the complex relationships between TGF-beta 1 and cellular regulation.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7958985     DOI: 10.1016/0378-1119(94)90408-1

Source DB:  PubMed          Journal:  Gene        ISSN: 0378-1119            Impact factor:   3.688


  5 in total

Review 1.  Strategy for designing specific antisense oligonucleotide sequences.

Authors:  M Mitsuhashi
Journal:  J Gastroenterol       Date:  1997-04       Impact factor: 7.527

2.  Silencing of the TGF-β1 gene increases the immunogenicity of cells from human ovarian carcinoma.

Authors:  Huafeng Wei; Pu Liu; Elizabeth Swisher; Yuen Yee Yip; Jee Hang Tse; Kathy Agnew; Karl Erik Hellström; Ingegerd Hellström
Journal:  J Immunother       Date:  2012-04       Impact factor: 4.456

Review 3.  Medical applications of transforming growth factor-beta.

Authors:  Kathleen C Flanders; James K Burmester
Journal:  Clin Med Res       Date:  2003-01

4.  Sequence-specific inhibition of gene expression by a novel antisense oligodeoxynucleotide phosphorothioate directed against a nonregulatory region of the human immunodeficiency virus type 1 genome.

Authors:  M I Anazodo; M A Wainberg; A D Friesen; J A Wright
Journal:  J Virol       Date:  1995-03       Impact factor: 5.103

Review 5.  Antisense Oligonucleotides Targeting Angiogenic Factors as Potential Cancer Therapeutics.

Authors:  Bao T Le; Prithi Raguraman; Tamer R Kosbar; Susan Fletcher; Steve D Wilton; Rakesh N Veedu
Journal:  Mol Ther Nucleic Acids       Date:  2018-11-20
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.